Yan Yu

3.2k total citations
82 papers, 1.4k citations indexed

About

Yan Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yan Yu has authored 82 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Yan Yu's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Diagnosis and Treatment (14 papers) and Lung Cancer Research Studies (13 papers). Yan Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Diagnosis and Treatment (14 papers) and Lung Cancer Research Studies (13 papers). Yan Yu collaborates with scholars based in China, United States and Germany. Yan Yu's co-authors include Rong Deng, Xuan Li, Jiao Ji, Lin Jiao, Xiao‐Feng Zhu, Rui-Yan Wu, Gong-Kan Feng, Hai‐Liang Zhang, Dandan Li and Ting Sun and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Yan Yu

74 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yan Yu China	18	745	403	349	346	271	82	1.4k
Xianling Guo China	22	950 1.3×	369 0.9×	609 1.7×	492 1.4×	138 0.5×	47	1.7k
Hao Wen China	26	981 1.3×	517 1.3×	203 0.6×	453 1.3×	274 1.0×	103	2.1k
Bingyin Shi China	25	1.1k 1.5×	355 0.9×	154 0.4×	342 1.0×	232 0.9×	87	1.9k
Xiaoxi Lv China	23	897 1.2×	296 0.7×	408 1.2×	298 0.9×	351 1.3×	43	1.7k
Wenting Liu China	18	512 0.7×	210 0.5×	231 0.7×	212 0.6×	113 0.4×	58	1.3k
Hanxiang Zhan China	20	573 0.8×	394 1.0×	151 0.4×	420 1.2×	120 0.4×	41	1.1k
Kyoung Min Kim South Korea	22	626 0.8×	216 0.5×	165 0.5×	606 1.8×	397 1.5×	65	1.4k
Xuelai Luo China	29	1.6k 2.1×	768 1.9×	215 0.6×	422 1.2×	250 0.9×	62	2.2k
Limei Liu China	22	1.1k 1.5×	507 1.3×	148 0.4×	565 1.6×	125 0.5×	42	1.7k

Countries citing papers authored by Yan Yu

Since Specialization

Citations

This map shows the geographic impact of Yan Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Yu more than expected).

Fields of papers citing papers by Yan Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Yu. The network helps show where Yan Yu may publish in the future.

Co-authorship network of co-authors of Yan Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Yu. A scholar is included among the top collaborators of Yan Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Yu. Yan Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Xin, Meng Zhang, Wenbin Jiang, et al.. (2025). Integrating multi-omics to unveil PSMD12 as a critical gene in promoting brain metastases of lung adenocarcinoma. Journal of Translational Medicine. 23(1). 668–668.

Cheng, Ying, Jie Wang, Yan Yu, et al.. (2025). Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer. Clinical Cancer Research. 31(14). 2926–2934. 1 indexed citations

Lv, Dongqing, Weineng Feng, Shuyu Liu, et al.. (2024). 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China. Annals of Oncology. 35. S1661–S1661.

Xing, Puyuan, Dongqing Lv, Weineng Feng, et al.. (2024). 677P Comparison of performance of MET amplification detection by FISH, NGS and ddPCR in EGFRm advanced NSCLC patients post first-line osimertinib treatment failure: Analysis from a prospective, multi-center study in China. Annals of Oncology. 35. S1658–S1658.

Geng, Jianxiong, et al.. (2024). IL-34 and its receptors as predictors of brain metastasis and prognosis in lung adenocarcinoma: Unveiling insights through bioinformatic and immunohistochemical investigations. Heliyon. 10(13). e33791–e33791. 1 indexed citations

Lü, Shun, Jiong Wu, Jiang Jin, et al.. (2024). Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. Journal of Clinical Oncology. 43(2). 143–153. 5 indexed citations

Wang, Jie, Xiaohua Yu, Y. Hu, et al.. (2024). Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial. ESMO Open. 9(10). 103727–103727. 13 indexed citations

Cheng, Ying, Lin Wu, Yong Fang, et al.. (2024). Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Research. 84(7_Supplement). CT248–CT248. 5 indexed citations

Zhou, Qing, Jie Li, Shundong Cang, et al.. (2024). FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. Clinical Lung Cancer. 26(2). 152–157.e1. 4 indexed citations

10.

Wu, Yi‐Long, Qing Zhou, Jie Wang, et al.. (2023). Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant ( EGFR m ⁺ ) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.. Journal of Clinical Oncology. 41(16_suppl). 9001–9001. 8 indexed citations

11.

Wang, Jie, Zhijie Wang, Lin Wu, et al.. (2023). Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.. Journal of Clinical Oncology. 41(16_suppl). 9003–9003. 4 indexed citations

12.

Planchard, David, Pasi A. Jänne, Ying Cheng, et al.. (2023). 512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC. Annals of Oncology. 34. S1668–S1668.

13.

Yang, Yunpeng, Jie Min, Nong Yang, et al.. (2023). Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduction and Targeted Therapy. 8(1). 301–301. 15 indexed citations

14.

Huang, Yan, Qitao Yu, Nong Yang, et al.. (2023). Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9080–9080. 2 indexed citations

15.

Lü, Shun, Wei Hong, Nong Yang, et al.. (2023). Abstract CT204: Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody-drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study. Cancer Research. 83(8_Supplement). CT204–CT204. 2 indexed citations

16.

Wei, Zixin, et al.. (2022). Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis. Future Oncology. 18(18). 2257–2267. 8 indexed citations

17.

Shi, Yuankai, Xin Zhang, Gang Wu, et al.. (2022). Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study. The Lancet Regional Health - Western Pacific. 23. 100452–100452. 10 indexed citations

18.

Lu, Shiyuan, et al.. (2022). 111P Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours. Annals of Oncology. 33. S83–S84. 1 indexed citations

19.

Xu, Yan, Hongqing Zhuang, Hua Zhang, et al.. (2021). Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique. Thoracic Cancer. 12(23). 3157–3168. 10 indexed citations

20.

Chu, Tianqing, Jun Lü, Minghong Bi, et al.. (2021). Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer Biology and Medicine. 18(3). 816–824. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact